NeoGenomics Earnings Analysis: Q1 Recap
NeoGenomics Earnings Analysis: Q1 Recap
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.
NeoGenomics（納斯達克股票代碼：NEO）的第一季度收益報告已於2024年4月30日星期二上午7點30分發布。
Here's what investors need to know about the latest announcement.
以下是投資者需要了解的有關最新公告的信息。
Earnings
收益
NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
NeoGenomics的收益比預期高出60.0％，每股收益爲-0.02美元，而估計爲-0.05美元。
Revenue was up $19.02 million from the same period last year.
收入比去年同期增長了1,902萬美元。
Analysis of Past Earnings
過去收益分析
Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day.
上個季度，該公司的每股收益高出0.05美元，隨後第二天股價上漲了12.0％。
Here's a look at NeoGenomics's past performance:
以下是新基因組學過去的表現：
| Quarter | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.02 | -0.08 | -0.11 | -0.15 |
| EPS Actual | -0.02 | 0.03 | 0 | -0.05 | -0.09 |
| Revenue Estimate | 149.89M | 152.54M | 142.00M | 137.42M | 126.39M |
| Revenue Actual | 156.24M | 155.55M | 151.95M | 146.92M | 137.22M |
| 季度 | 2024 年第一季度 | 2023 年第四季度 | 2023 年第三季度 | 2023 年第二季度 | 2023年第一季度 |
|---|---|---|---|---|---|
| 每股收益估算 | -0.05 | -0.02 | -0.08 | -0.11 | -0.15 |
| 實際每股收益 | -0.02 | 0.03 | 0 | -0.05 | -0.09 |
| 收入估算 | 149.89 億 | 152.54 億 | 142.00 億 | 137.42 億 | 126.39 億 |
| 實際收入 | 156.24 億 | 155.55 億 | 151.95 億 | 146.92 億 | 137.22 億 |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
新投資者應注意，有時對股票價格影響最大的不是收益超過或失敗，而是指導方針（或預測）。
Guidance
指導
NeoGenomics management provided guidance for FY 2024, expecting earnings between $0.0 and $0.04 per share.
NeoGenomics管理層爲2024財年提供了指導，預計每股收益在0.0美元至0.04美元之間。
Recent Earnings Releases from Competitors
競爭對手發佈的最新業績
With NeoGenomics's earnings data in hand, it's essential to compare its metrics to those of similar companies, including BrightSpring Health, Guardant Health, and R1 RCM.
有了NeoGenomics的收益數據，將其指標與包括BrightSpring Health、Guardant Health和R1 RCM在內的類似公司的指標進行比較至關重要。
- BrightSpring Health's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.12 compared to the estimated EPS of $0.07, resulting in a 71.43% increase.
- The latest earnings announcement from Guardant Health on May 09, 2024 exceeded expectations, with an actual EPS of $-0.46 compared to the market's estimate of $-0.85, resulting in a 45.88% increase.
- On May 08, 2024, R1 RCM unveiled earnings that were below market expectations, with an actual EPS of $-0.08 compared to an estimated EPS of $-0.01, resulting in a -700.0% decrease.
- BrightSpring Health在2024年5月2日的收益超出了市場預期，顯示每股收益爲0.12美元，而估計的每股收益爲0.07美元，增長了71.43％。
- Guardant Health於2024年5月9日發佈的最新收益超出了預期，實際每股收益爲-0.46美元，而市場預期的爲-0.85美元，增長了45.88％。
- 2024年5月8日，R1 RCM公佈的收益低於市場預期，實際每股收益爲-0.08美元，而估計的每股收益爲-0.01美元，下降了-700.0％。
Competitors Quarterly Earnings and Stock Performance Analysis
競爭對手的季度收益和股票表現分析
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.
該分析提供了對市場對主要競爭對手最新業績的反應的見解。它重點介紹了每家公司的預期和已公佈的每股收益（EPS），以及公告日收盤時和下一個交易日開盤時的相應股價。
| Company Name | Date | EPS Expected | EPS Announced | EPS Change Percent | Stock Price At Close | Stock Price at Next Day Open | Price Change Percent |
|---|---|---|---|---|---|---|---|
| NeoGenomics | April 30, 2024 | -0.05 | -0.0260.0% | $13.92 | $14.0 | 0.57% | |
| BrightSpring Health | May 02, 2024 | 0.07 | 0.1271.43% | $11.06 | $11.27 | 1.9% | |
| Guardant Health | May 09, 2024 | -0.85 | -0.4645.88% | $19.44 | $21.84 | 12.35% | |
| R1 RCM | May 08, 2024 | -0.01 | -0.08-700.0% | $12.84 | $12.67 | -1.32% |
| 公司名 | 日期 | 預期每股收益 | 每股收益公佈 | 每股收益變化百分比 | 收盤時股價 | 次日開盤時的股價 | 價格變動百分比 |
|---|---|---|---|---|---|---|---|
| 新基因組學 | 2024年4月30日 | -0.05 | -0.0260.0% | 13.92 美元 | 14.0 美元 | 0.57% | |
| 光明春日健康 | 2024 年 5 月 2 日 | 0.07 | 0.1271.43% | 11.06 美元 | 11.27 美元 | 1.9% | |
| 守護者生命值 | 2024年5月9日 | -0.85 | -0.4645.88% | 19.44 美元 | 21.84 美元 | 12.35% | |
| R1 RCM | 2024年5月8日 | -0.01 | -0.08-700.0% | 12.84 美元 | 12.67 美元 | -1.32% |
Analyzing Peer Revenue Discrepancy: Estimated vs. Announced
分析同行收入差異：估計值與公佈收入差異
The comparison table below presents estimated and announced revenue figures for NeoGenomics's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.
下表顯示了NeoGenomics同行的估計和公佈的收入數據。這種比較可以深入了解這些公司的收入表現，爲了解其在行業中的財務狀況提供了寶貴的背景信息。
| Company Name | Estimated Revenue | Announced Revenue | Revenue Surprise Percentage |
|---|---|---|---|
| NeoGenomics | 149.89M | 156.24M | 4.24% |
| BrightSpring Health | 2.31B | 2.58B | 11.56% |
| Guardant Health | 150.67M | 168.49M | 11.83% |
| R1 RCM | 611.93M | 603.90M | -1.31% |
| 公司名 | 預計收入 | 公佈的收入 | 收入意外百分比 |
|---|---|---|---|
| 新基因組學 | 149.89 億 | 156.24 億 | 4.24% |
| 光明春日健康 | 2.31B | 2.58B | 11.56% |
| 守護者生命值 | 150.67 億 | 168.49 億 | 11.83% |
| R1 RCM | 611.93 億 | 603.90 億 | -1.31% |
To track all earnings releases for NeoGenomics visit their earnings calendar here.
要追蹤NeoGenomics的所有業績，請在此處訪問他們的業績日曆。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由Benzinga的自動內容引擎生成，並由編輯審閱。
譯文內容由第三人軟體翻譯。